Drugs / EVOCALCET
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04206657 | Dec 2019 → Jun 2021 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02143271 | May → Dec 2014 | secondary hyperparathyroidism | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01935856 | Aug 2013 → Mar 2014 | hyperparathyroidism | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02216656 | Jul 2014 → Feb 2015 | secondary hyperparathyroidism of renal origin | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02549391 | Sep 2015 → Nov 2016 | secondary hyperparathyroidism | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT03822507 | Apr 2019 → Sep 2021 | secondary hyperparathyroidism of renal origin | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03280264 | Aug 2017 → Apr 2019 | parathyroid gland carcinoma, primary hyperparathyroidism | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02549417 | Sep 2015 → Dec 2016 | secondary hyperparathyroidism of renal origin | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02549404 | Sep 2015 → Dec 2016 | secondary hyperparathyroidism | Kyowa Kirin, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVOCALCET | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297621 ↗ |
| Known as | KHK7580 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02549417 ↗ |
| Known as | MT-4580 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297621 ↗ |
| Action | Activate | “Calcium sensing receptor positive allosteric modulator” CHEMBL4297621 ↗ |
| Modality | Small molecule | — CHEMBL4297621 ↗ |
| Route | Oral | “Oral administration” NCT01935856 ↗ |
| Target | CASR | “Calcium sensing receptor positive allosteric modulator” CHEMBL4297621 ↗ |